Abstract
Information processing speed (IPS) is a core cognitive process, highly relevant in eve-ryday-life and the most frequent and disabling cognitive symptom in patients with Relapsing Multiple Sclerosis (pwRMS). By using regionally-specific focalized transcranial direct current stimulation (tDCS) in healthy individuala and pwRMS, we provide causal evidence for superior parietal lobe (SPL) involvement in IPS and identfied a clinical predictor of tDCS-response in pwRMS. The study employed a registered, randomized, sham-tDCS controlled, three-way blind-ed, cross-over trial and a mixed-factors design with eight arms [between-subjects: group (pwRMS, controls); tDCS-polarity (excitatory, inhibitory); within-subjects: stimulation (active-, sham-tDCS)]. Concurrently with tDCS, participants completed a computerized version of the Symbol-Digit-Modalities-Test (SDMT), the current gold standard for quantifying IPS impairment in pwRMS. Bayesian modeling with generalized linear mixed models provided strong evidence for polarity specific modulation of IPS by SPL-tDCS and a double-dissociation of stimulation response in pwRMS and controls. Healthy individuals showed the canonical pattern of signifi-cantly enhanced and reduced processing speed during excitatory or inhibitory tDCS. In pwRMS, a reversed pattern was found and tDCS-response was predicted by baseline SDMT performance; i.e., more or less impaired patients benefited from inhibitory or excitatory tDCS, respectively. Our results provide direct causal evidence for SPL involvement in IPS in health and disease and suggest that the degree of IPS impairment in pwRMS reflects compensatory or dysfunctional neuroplastic processes that can be counteracted in a polarity specific way. Identified standardized transition scores for the effectiveness of excitatory or inhibitory tDCS will inform future individ-ually-tailored stimulation protocols in pwRMS.
One Sentence Summary Polarity-specific modulation of information processing speed in mul-tiple sclerosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04667221
Funding Statement
This research was partly supported by the German Research Foundation (Research Unit 5429/1 (467143400), SFB 1315 (327654276, B03) and project grants ME 3161/3-1; ME 3161/5-1, ME 3161/6-1; FL 379/35-1; FL 379/34-1) and the European Fonds for Regional Development (GHS-20-0007).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of the University Medicine Greifswald gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The experimental paradigm and data, as well as scripts for data analyses are available at open science framework (OSF).
